Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT

Add to watchlist

$17.44

+0.42

+2.47%

Market closed

Open in about 13 hours

-26.51%

month

-26.51%

quarter

-48.03%

year

Market Cap	417.14M
Enterprise value	412.20M

P/E	77.06
EV/Sales	1.72
EV/EBITDA	-7.03
Price/Sales	2.99
Price/Book	2.63
PEG ratio	0.73
EPS	-3.91

Revenue	113.75M
EBITDA	-106.49M
Income	-104.16M
Revenue Q/Q	-59.11%
Revenue Y/Y	-59.40%

Profit margin	-26.59%
Oper. margin	-25.3%
Gross margin	5.61%
EBIT margin	-25.3%
EBITDA margin	-93.62%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Arcturus Therapeutics Holdings Stock Forecast

M Q Y

Last Year

$73

Potential upside: 318.57%

Analysts Price target
Financials & Ratios estimates

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Profit margin
Jun 2023	9.56M	-52.55M	-549.4%
Sep 2023	43.37M	-16.22M	-37.4%
Dec 2023	28.21M	-8.57M	-30.39%
Mar 2024	32.59M	-26.81M	-82.27%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Debt to assets
Jun 2023	430646000	145.47M	33.78%
Sep 2023	457650000	177.58M	38.8%
Dec 2023	429402000	150.88M	35.14%
Mar 2024	418849000	154.87M	36.98%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Cash Flow
Jun 2023	50.80M	-354K	94K
Sep 2023	-32.40M	-981K	21.84M
Dec 2023	-544.67K	-837.07K	-17.98M
Mar 2024	-5.55M	-240K	2.18M

Arcturus Therapeutics Holdings alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Arcturus Therapeutics Holdings
Employees

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Employee count
Aug 2023	170
Sep 2023	170
Oct 2023	170
Nov 2023	170
Dec 2023	170
Jan 2024	170
Feb 2024	170
Mar 2024	180
Apr 2024	180
May 2024	180
Jun 2024	180
Jul 2024	180

Arcturus Therapeutics Holdings
Hedge Funds Holdings Q1 2023

61.51% -24.62%

of ARCT is owned by hedge funds

84 -29

hedge funds hold ARCT stock

16.66M -6.13M

shares is hold by hedge funds

ARCT hedge funds holdings changes

Arcturus Therapeutics Holdings
Insider Trading

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Insider trades (number of shares)
Period	Buy	Sel
Mar 2024	0	26000
Jun 2024	0	76114
Oct 2024	0	12000

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	15 Oct 2024	CHIVUKULA PAD officer: Chief Scientific Officer & COO officer: Chief Scientific Offic..	Common Stock	12,000	$20.76	$249,120
Option	14 Jun 2024	MARANTZ JING L. director director	Common Stock	3,131	N/A	N/A
Option	14 Jun 2024	MARANTZ JING L. director director	Deferred Stock Units	3,131	N/A	N/A
Option	14 Jun 2024	HOLMES EDWARD W director director	Common Stock	3,131	N/A	N/A
Option	14 Jun 2024	HOLMES EDWARD W director director	Deferred Stock Units	3,131	N/A	N/A
Option	14 Jun 2024	MARKELS JOHN director director	Common Stock	3,131	N/A	N/A
Option	14 Jun 2024	MARKELS JOHN director director	Deferred Stock Units	3,131	N/A	N/A
Option	14 Jun 2024	MARQUET MAGDA director director	Common Stock	3,131	N/A	N/A
Option	14 Jun 2024	MARQUET MAGDA director director	Deferred Stock Units	3,131	N/A	N/A
Option	14 Jun 2024	BARLOW JAMES F director director	Common Stock	3,131	N/A	N/A

ARCT insider trading transactions

Arcturus Therapeutics Holdings
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 8 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 7 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 14 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 7 Aug 2023	Q2 2023 Earnings Call Transcript

ARCT earnings call transcripts

Arcturus Therapeutics Holdings
Executives

Insider	Age	Compensation
Mr. Joseph E. Payne M.Sc. (1972) Founder, Pres, Chief Executive Officer & Director	53	$950,000
Dr. Steven George Hughes M.B.A., M.D. (1967) Chief Medical Officer	58	$664,000
Dr. Padmanabh Chivukula (1979) Founder, Chief Scientific Officer, Chief Operating Officer & Sec.	46	$640,000
Mr. Andrew H. Sassine (1964) Chief Financial Officer & Director	61	$640,000

Arcturus Therapeutics Holdings
Latest News

Monday, 16 December 2024
16:01	Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	businesswire.com
Tuesday, 26 November 2024
16:01	Arcturus Therapeutics to Attend Upcoming Investor Conferences	businesswire.com
Monday, 18 November 2024
20:00	Arcturus Therapeutics to Present at Jefferies London Healthcare Conference	businesswire.com
Thursday, 14 November 2024
13:44	Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data	seekingalpha.com
01:00	Meiji Seika Pharma Announces Investment in ARCALIS, Inc.	businesswire.com
Monday, 11 November 2024
16:01	Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial	businesswire.com
Thursday, 7 November 2024
23:24	Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript	seekingalpha.com
18:57	Arcturus Therapeutics (ARCT) Reports Q3 Loss, Lags Revenue Estimates	zacks.com
Monday, 4 November 2024
11:05	Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect	zacks.com
Wednesday, 30 October 2024
13:01	Arcturus Therapeutics (ARCT) Upgraded to Buy: What Does It Mean for the Stock?	zacks.com
Tuesday, 1 October 2024
11:51	ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty	zacks.com
Monday, 30 September 2024
08:00	Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination	prnewswire.com
Monday, 16 September 2024
12:31	Here's Why Investors Should Invest in Arcturus Stock Now	zacks.com
Friday, 13 September 2024
08:16	New Strong Buy Stocks for September 13th	zacks.com
08:15	Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma	prnewswire.com
Monday, 2 September 2024
10:55	Does Arcturus Therapeutics (ARCT) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?	zacks.com
Friday, 23 August 2024
13:01	What Makes Arcturus Therapeutics (ARCT) a New Strong Buy Stock	zacks.com
08:20	New Strong Buy Stocks for August 23rd	zacks.com
Friday, 9 August 2024
05:27	High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine	seekingalpha.com
Monday, 5 August 2024
20:50	Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript	seekingalpha.com
18:10	Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
16:01	Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress	businesswire.com
Thursday, 18 July 2024
19:30	Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024	businesswire.com
Thursday, 20 June 2024
08:00	Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors	businesswire.com
Saturday, 8 June 2024
02:42	Arcturus: A Hidden Gem In The Biotech Sector	seekingalpha.com
Friday, 7 June 2024
10:30	Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference	businesswire.com
Tuesday, 28 May 2024
06:30	Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program	businesswire.com
Monday, 20 May 2024
08:30	Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine	prnewswire.com
08:30	Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine	businesswire.com
Wednesday, 15 May 2024
16:01	Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences	businesswire.com

Ideas & Opinions

Seeking Alpha 8 Jun 2024

Arcturus: A Hidden Gem In The Biotech Sector
Seeking Alpha 30 May 2024

Vertex: Poised For Long-Term Growth Driven By Multiple Pipeline Catalysts
Seeking Alpha 23 Apr 2024

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Seeking Alpha 2 Feb 2024

Why Arcturus Therapeutics Has A Promising Future With Innovative CF And COVID Treatments
Seeking Alpha 31 Jan 2024

Arcturus: H1 2024 Rare Disease Drug Data On Deck
Seeking Alpha 17 Nov 2023

From Financial Metrics To mRNA Milestones: Arcturus Therapeutics' Evolving Journey
Seeking Alpha 7 Sep 2023

Arcturus: Interim Readout Of Rare Disease Data In Coming Months
Seeking Alpha 5 Sep 2023

Arcturus: mRNA Therapies For Rare Diseases Accelerate Towards Proof Of Concept
Seeking Alpha 26 Jun 2023

Arcturus Therapeutics: A Beacon Of Hope For Rare Diseases Amid The mRNA Race
Seeking Alpha 11 Apr 2023

Unlocking Arcturus' Potential And De-Risking Through Partnerships

Frequently Asked Questions (FAQ)

What's the price of Arcturus Therapeutics Holdings stock today?

One share of Arcturus Therapeutics Holdings stock can currently be purchased for approximately $17.44.
When is Arcturus Therapeutics Holdings's next earnings date?

Unfortunately, Arcturus Therapeutics Holdings's (ARCT) next earnings date is currently unknown.
Does Arcturus Therapeutics Holdings pay dividends?

No, Arcturus Therapeutics Holdings does not pay dividends.
How much money does Arcturus Therapeutics Holdings make?

Arcturus Therapeutics Holdings has a market capitalization of 417.14M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 23.33% to 157.75M US dollars.
What is Arcturus Therapeutics Holdings's stock symbol?

Arcturus Therapeutics Holdings Inc. is traded on the NASDAQ under the ticker symbol "ARCT".
What is Arcturus Therapeutics Holdings's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Arcturus Therapeutics Holdings?

Shares of Arcturus Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Arcturus Therapeutics Holdings's key executives?
Arcturus Therapeutics Holdings's management team includes the following people:
- Mr. Joseph E. Payne M.Sc. Founder, Pres, Chief Executive Officer & Director(age: 53, pay: $950,000)
- Dr. Steven George Hughes M.B.A., M.D. Chief Medical Officer(age: 58, pay: $664,000)
- Dr. Padmanabh Chivukula Founder, Chief Scientific Officer, Chief Operating Officer & Sec.(age: 46, pay: $640,000)
- Mr. Andrew H. Sassine Chief Financial Officer & Director(age: 61, pay: $640,000)
Is Arcturus Therapeutics Holdings founder-led company?

Yes, Arcturus Therapeutics Holdings is a company led by its founders Mr. Joseph E. Payne M.Sc. and Dr. Padmanabh Chivukula.
How many employees does Arcturus Therapeutics Holdings have?

As Jul 2024, Arcturus Therapeutics Holdings employs 180 workers.
When Arcturus Therapeutics Holdings went public?

Arcturus Therapeutics Holdings Inc. is publicly traded company for more then 12 years since IPO on 22 May 2013.
What is Arcturus Therapeutics Holdings's official website?

The official website for Arcturus Therapeutics Holdings is arcturusrx.com.
Where are Arcturus Therapeutics Holdings's headquarters?

Arcturus Therapeutics Holdings is headquartered at 10628 Science Center Drive, San Diego, CA.
How can i contact Arcturus Therapeutics Holdings?

Arcturus Therapeutics Holdings's mailing address is 10628 Science Center Drive, San Diego, CA and company can be reached via phone at 858 900 2660.
What is Arcturus Therapeutics Holdings stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Arcturus Therapeutics Holdings in the last 12 months, the avarage price target is $73. The average price target represents a 318.57% change from the last price of $17.44.

Arcturus Therapeutics Holdings Inc.

arcturusrx.com

Exchange:

NASDAQ

Full time employees:

180

Industry:

Biotechnology

Sector:

Healthcare

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

858 900 2660

10628 Science Center Drive
San Diego, CA 92121

CIK: 0001768224
ISIN: US03969T1097
CUSIP: 03969T109